Bavarian Nordic (OTCMKTS:BVNRY) Shares Gap Down – What’s Next?

Bavarian Nordic (OTCMKTS:BVNRY)’s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $11.44, but opened at $10.88. Bavarian Nordic shares last traded at $10.88, with a volume of 556 shares trading hands.

Bavarian Nordic Trading Down 4.1%

The firm has a fifty day moving average of $9.77 and a two-hundred day moving average of $9.77. The company has a market capitalization of $2.59 billion, a PE ratio of 10.99 and a beta of 1.20.

Bavarian Nordic (OTCMKTS:BVNRY) last announced its quarterly earnings results on Friday, August 21st. The company reported $0.46 earnings per share (EPS) for the quarter. The business had revenue of $316.47 million for the quarter. Bavarian Nordic had a net margin of 24.36% and a return on equity of 12.06%.

Bavarian Nordic Company Profile

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.